FDA finalises mobile medical applications guidance
On 23 September 2013, the Food and Drug Administration (FDA) released the long-awaited mobile medical applications final guidance. Coming more than two years after its initial draft, the final guidance provides further clarity and insight into the FDA’s current thinking on the regulation of applications meant to run on a mobile platform or on a browser tailored for use on a mobile platform.
Following release of the earlier draft guidance, the FDA solicited public comment and reportedly received more than 130 such comments. According to the agency, the comments were largely supportive of the FDA’s general proposed approach. Consistent with that view, the final guidance proposes the same fundamental approach to regulation of mobile medical apps as was featured in the draft guidance…
If you are registered and logged in to the site, click on the link below to read the rest of the Hogan Lovells briefing. If not, please register or sign in with your details below.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
The decision of the US Court of Appeals has raised questions about how issuers should present their disclosures on conflict minerals under Exchange Act Rule 13p-1 and Form SD.
An interesting judgment was delivered by the Honourable J Majiki on 19 November 2013 in the Eastern Cape High Court, Port Elizabeth.
Analysis from The Lawyer
As international firms question their future in these small, closely linked markets, local lawyers too are eyeing the business environment with caution
Beyond the headline infrastructure projects, UK construction work is still recovering from the clobbering it took during the slump